CTRI/2024/04/065369尚未招募2 期
A Comparative Pharmacokinetic Profiles of Three Urolithin A Formulations in Healthy Volunteers: A Randomized, Open-label, Single-dose, Parallel-arm Study - NI
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Amazentis SA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy male and female participants aged between 18 and 45 years (both inclusive); 2.Non-smoker subject or smoker of not more than 5 cigarettes a day; 3.Body Mass Index (BMI) between 18.50-30.00 kg/m2 inclusive; 4.Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests), individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator; 5.Normal ECG recording on a 12-lead ECG and/or chest X-ray (PA view) significant at the screening visit or considered not clinically significant (NCS) by investigators; 6.A negative alcohol breath test result at housing; 7.Trial participant able to communicate effectively, provide voluntary written informed consent and available for the entire study duration; 8.Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee; 9.Ability to fast for at least 14.00 hours and consume standard meals; 10.Accept to refrain consuming certain foods and supplements at least two weeks before inclusion; 11.Female participants must have a negative urine pregnancy test prior to housing; 12.Trial participants that can provide adequate evidence of their identity; 13.The participants agree to refrain from consuming dietary supplements that could potentially impact either muscle or mitochondrial function or contain Urolithin A, such as resveratrol, pomegranate and ellagitannins, nicotinamide riboside, whey protein, leucine, iso-leucine, l-carnitine, creatinine, coenzyme Q10, vitamin A, niacin, folic acids, vitamin C, vitamin E and probiotic foods and supplements, during the 2 weeks before inclusion and throughout the study; 14.Females of childbearing potential agree to use appropriate contraceptive measures like non-hormonal intrauterine devices, barrier methods, and spermicidal agents during the study and 07 days after completion of the study; 15.Male agreeing to use appropriate contraceptive measures like the Double Barrier method (Condom), and should not donate sperm, etc. during the study and 07 days after completion of the study.
排除标准
- •1.Known hypersensitivity to Urolithin A or related product or any component of intervention, presence or history of drug hypersensitivity, allergic disease or lactose intolerance;
- •2.Any history or presence of clinically significant medical condition, such as, but not limited to, cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease, thyroid disease, adrenal dysfunction, or organic intracranial lesion;
- •3.Any treatment which could bring about induction or inhibition of the hepatic microsomal enzyme system within one month of starting the study;
- •4.History or presence of alcoholism or drug abuse;
- •5.History or presence of gastric and/or duodenal ulceration;
- •6.History or presence of cancer;
- •7.Difficulty with donating blood;
- •8.Use of any prescribed medication (including herbal remedies) during the two weeks before the start of the study or OTC medicinal products (including herbal remedies) during the week before study initiation and throughout the study;
- •9.Use of medications such as benzodiazepines, anticonvulsants, or barbiturates for one month before the start of the study and throughout the study;
- •10.Trial participant consumed tobacco/tobacco-containing products, pan or pan masala, gutkha, and masala (containing beetle nut and tobacco) for at least 48.00 hours before initiation of the study and throughout the study;
- •11.Trial participant consumed caffeine and/or xanthine-containing foods or beverages (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and grapefruit juice and poppy-containing foods for at least 48.00 hours before initiation of the study and throughout the study;
- •12.Major illness during the 90 days before screening;
- •13.Participation in a drug research study within 90 days of screening;
- •14.Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C, and VDRL;
- •15.History or presence of easy bruising or bleeding;
- •16.Abnormal diet pattern for whatever reason (e.g., low sodium, fasting, and high protein diets) during the four weeks preceding the study;
- •17.Females of childbearing potential with any one of the following reported and documented on the medical history:
- •i.Postmenopausal with spontaneous amenorrhea for at least one year, or
- •ii.Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
- •iii.Total hysterectomy and an absence of bleeding for at least 3 months;
- •iv.Female volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 07 days before dosing;
- •18.Pregnant women and nursing mothers;
- •19.Male and females of childbearing potential unwilling to employ appropriate and reliable method of contraception like non-hormonal intrauterine devices, barrier methods, and spermicidal agents, Double Barrier method (Condom) during the study till 07 days after the completion of the study;
- •20.Male volunteers willing to donate sperm during the study till 07 days after the completion of the study.
研究者
相似试验
已完成
不适用
Comparison of the pharmacokinetics between the initial and reduced dose of S-1 in the patients with locally advanced head and neck cancerlocally advanced head and neck cancerJPRN-UMIN000025205ational Cancer Center Hospital East25
已完成
不适用
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight versus Higher Body Weight Aspirin-Treated Subjects with Stable Coronary Artery Diseaseillness of coronary arteries10011082Coronary Artery DiseaseNL-OMON34026Eli Lilly25
进行中（未招募）
不适用
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis - TABREUCTR2005-005292-15-SEEli Lilly and Company Ltd.110
已完成
不适用
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly versus Non-Elderly Aspirin-Treated Subjects with Stable Coronary Artery DiseaseCoronary Artery Diseaseillness of coronary arteries10011082NL-OMON34156Eli Lilly20
撤回
不适用
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight versus Higher Body Weight Aspirin-Treated Subjects with Stable Coronary Artery Diseaseillness of coronary arteries10011082Coronary Artery DiseaseNL-OMON32918Eli Lilly25